Treatment News : HIV Docs Believe Meds Prevent Transmission, But Don’t Start ARVs Early

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » December 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

December 10, 2012

HIV Docs Believe Meds Prevent Transmission, But Don’t Start ARVs Early

HIV clinicians widely believe in the antiretroviral (ARV) treatment as prevention model, but they don’t necessarily apply the concept to individual patients, with only one in seven clinicians immediately starting treatment in patients, a new study has found. Published in the recent issue of the Journal of Acquired Immune Deficiency Syndromes, the paper examined the AVR-prescribing patterns and attitudes about treatment initiation among 38 health care providers in the Bronx, New York, and Washington, DC—a sample that the researchers felt might be comparable with other urban clinicians across the country.

Polling 165 physicians, nurse practitioners and physician assistants through an Internet-based survey, the research team from New York University, Fenway Health, Harvard, and other research groups found that 95 percent “strongly agreed” or “agreed” that early initiation of ARVs can lower transmission rates. Similar to the 55 percent of the Department of Health and Human Services guideline panel that in 2010 recommended beginning HIV therapy when CD4 counts drop below 500, 56 percent of the HIV clinicians polled favored starting therapy at CD4 levels between 350 and 500.

Meanwhile, only 14 percent encouraged patients to begin therapy immediately, regardless of CD4 counts. However, 75 percent recommended early therapy for patients in serodiscordant relationships, and 40 percent did so for those having unprotected sex with a partner with an unknown HIV status.

“There remains an inherent tension in prescribing [ARVs] to individuals for a population-benefit,” the researchers write, “when the risk-benefit profiles of multidecades-long treatment are not yet available. Nonetheless, there is emerging evidence that [ARV] initiation at higher [CD4] counts may have individual benefit.”

The paper goes on to say that, “Our findings suggest that clinicians will need to continue to balance emerging information regarding efficacy of [ARV] for prevention with their duty to provide patients with interventions that have a favorable long-term benefit to their own health.”

To read the study’s abstract, click here.

Search: HIV, treatment as prevention, antiretroviral, ARV, clinician, begin, Journal of Acquired Immune Deficiency Syndromes, Bronx, New York, Washington, DC, New York University, Fenway Health, Harvard, Department of Health and Human Services, guideline panel, serodiscordant relationships, unprotected sex.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.